HES Flare: GSK's Nucala Edges Forward
Marketing Submissions Expected In 2020
Executive Summary
GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.
You may also be interested in...
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
GSK Has High Hopes For COPD Vaccine
By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive pulmonary disease, which is expected to become the third leading cause of death worldwide by the end of the decade.
AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.